Invesco India Pharma and Healthcare Fund
Invesco Mutual Fund · Sectoral/Thematic · Direct plan, growth option
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | n/a | -5.4% | -3.1% |
| 3 months | n/a | -2.8% | 3.0% |
| 6 months | n/a | 8.9% | 21.7% |
| Year to date | n/a | -2.0% | 17.3% |
| 1 year | n/a | 1.4% | 17.5% |
| 3 years (CAGR) | n/a | 13.0% | 20.8% |
| 5 years (CAGR) | n/a | 12.0% | 15.3% |
| 7 years (CAGR) | n/a | 17.0% | 24.9% |
| 10 years (CAGR) | n/a | 14.6% | 14.7% |
| Since first NAV (CAGR) | n/a | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | n/a | 11.8% |
| 3Y rolling median | n/a | 17.5% |
| 3Y rolling worst | n/a | 3.0% |
| 3Y periods positive | n/a | 100% |
| 3Y periods ahead of benchmark | n/a | 84% |
| 5Y rolling median | n/a | 15.6% |
| 5Y rolling worst | n/a | 1.8% |
| 5Y periods ahead of benchmark | n/a | 91% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | n/a | 16.7% |
| Sharpe ratio | n/a | 0.42 |
| Sortino ratio | n/a | 0.63 |
| Beta | n/a | 0.96 |
| Alpha (ann.) | n/a | 3.7% |
| Upside capture | n/a | 106.94 |
| Downside capture | n/a | 95.17 |
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | n/a | −23.1% |
| Maximum drawdown, last 10Y | n/a | −38.3% |
| Maximum drawdown, last 5Y | n/a | −22.3% |
| Current drawdown | n/a | −8.3% |
| Recovery time of worst fall | n/a | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
This scheme invests mainly in the markets below, which are also close to how many of them are benchmarked. Where those markets stand today:
- P/E 40.7: higher than 94% of days since 2023 (median 34.6)
- 1Y +21.5% · 3Y +19.9% p.a. · 5Y +13.1% p.a. (index fund NAV, after costs)
- −3.2% from its 52-week high
- P/E 41.9: higher than 78% of days since 2023 (median 39.1)
- 1Y +12.4% · 3Y n/a p.a. · 5Y n/a p.a. (index fund NAV, after costs)
- −5.0% from its 52-week high (proxy NAV)
- P/E 21.6: higher than 1% of days since 2023 (median 24.2)
- 1Y −3.9% · 3Y +8.9% p.a. · 5Y +8.6% p.a. (index fund NAV, after costs)
- −9.3% from its 52-week high
Index levels and P/E: NSE daily index closing values; gold and silver: IBJA rates; returns: growth NAV of an index fund or ETF tracking the market (AMFI), so they are after that fund's costs. Context only: a market's level or valuation does not tell you how any scheme will perform. Explore all markets.
The Regular plan's expense ratio is 5.19% a year and the Direct plan's 3.30%, a gap of 1.89%. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹30,44,941.
With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.
TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.
- 1 Oct 2026: TER increased from 0.59% to 3.30% (AMFI TER disclosure)
- 7 Sep 2026: fund manager from this date: Aditya Khemani (Scheme Summary Document)
| Fund manager | Role | Managing since |
|---|---|---|
| Aditya Khemani | 7 Sep 2026 |
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Direct plan | 3.30% | 1.15% |
| AUM, whole scheme (₹ crore) | n/a | 1,272 |
| Riskometer | n/a | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
| Measure | Scheme | Benchmark / category |
|---|
Category consistency: last 10 years of month-ends, Sectoral/Thematic Direct plans; how it is calculated.
- What is the latest NAV of Invesco India Pharma and Healthcare Fund?
- The NAV of the Direct plan (growth option) was ₹9.5700 on 1 Oct 2026, as published by AMFI.
- Which category is Invesco India Pharma and Healthcare Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 253 Sectoral/Thematic schemes (Direct plans).
- What is the expense ratio (TER) of Invesco India Pharma and Healthcare Fund?
- The total expense ratio of the Direct plan is 3.30% a year, as disclosed to AMFI (median of Sectoral/Thematic Direct plans: 1.15%). It is already deducted from the NAV, so every return shown is after expenses.
- Who manages Invesco India Pharma and Healthcare Fund?
- According to its Scheme Summary Document, Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani (since 7 Sep 2026).
- What is the exit load of Invesco India Pharma and Healthcare Fund?
- As stated in its scheme documents: Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax Check the latest Scheme Information Document before investing, as loads can change.
- What is the minimum investment in Invesco India Pharma and Healthcare Fund?
- The minimum application amount is Rs. 1,000/- per application and in multiples of Re. 1/- thereafter. SIP details: SIP- Daily/Weekly/Monthly-Rs100, Quarterly: Rs 300, Fixed SWP-Weekly/Monthly: Rs 1000;Quarterly: Rs 1500, Fixed STP- Daily- Rs 500,Weekly/ Fortnightly/ Monthly: Rs 1000, Quarterly-Rs 1500.
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.